233728 Building Strategic Options

Wednesday, November 10, 2010 : 10:30 AM - 10:50 AM

Nicholas Reuter, MPH , Division of Pharmacologic Therapies, SAMHSA/CSAT, Rockville, MD
Accidental drug overdoses have increased dramatically over the last decade, with prescription opioid pain medications contributing the most to the increase. There has been a concomitant increase in the availability of these important medications. Survey instruments indicate that pain relievers are used for non medical use by at least 2% of the U.S. population, and each year more individuals initiate prescription drug abuse than any other illicit substance. Friends and relatives and individual physicians have been identified as the major source of these potent narcotics. Many recent studies have identified factors that increase the risk of overdose and overdose death with these medications. Applying this research, there are several Federal initiatives underway to reduce prescription drug diversion. In addition, other jurisdictions have implemented measures to reduce overdose deaths, with successful outcomes. The initiatives involve prescriber, dispenser, consumer education, and community outreach, together with expanded access to substance abuse treatment approaches. Nick Reuter will describe prescription overdose trends, prevention overdose strategies and potential Federal policy implications of naloxone protocol implementation.

Learning Areas:
Administer health education strategies, interventions and programs
Provision of health care to the public

Learning Objectives:
Explain the dynamics and complexities associated with the increase in opioid overdose mortality. Discuss Federal Government initiatives underway to reduce morbidity and mortality in cooperation with States, communities, and other stakeholders. Explain how successful risk reduction initiatives and treatment interventions can be expanded to specific populations.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been Team Leader of the Certification and Waiver Team and Senior Public Health Analyst, Division of Pharmacologic Therapies at CSAT for more than 6 years.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.